Wells Fargo Upgrades Celldex Therapeutics (CLDX) to Equal Weight
Tweet
Share
E-mailGet Alerts CLDX Hot Sheet
Price: $44.87 --0%
Rating Summary:
18 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 9 | New: 8
Rating Summary:
18 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 9 | New: 8
Join SI Premium – FREE
Wells Fargo analyst Derek Archila upgraded Celldex Therapeutics (NASDAQ: CLDX) from Underweight to Equal Weight with a price target of $27.00.
For an analyst ratings summary and ratings history on Celldex Therapeutics click here. For more ratings news on Celldex Therapeutics click here.
Shares of Celldex Therapeutics closed at $25.78 yesterday.
You May Also Be Interested In
- Northland Upgrades Hyliion Holdings (HYLN) to Outperform 'on Improved Visibility to KARNO Commercialization'
- Northcoast Upgrades CAVA Group Inc (CAVA) to Neutral
- JPMorgan Upgrades Kolmar Korea Co Ltd (161890:KS) to Overweight
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
